Aurinia Pharmaceuticals (AUPH) Income towards Parent Company (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Income towards Parent Company data on file, last reported at $34.4 million in Q1 2026.

• Quarterly Income towards Parent Company rose 47.17% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.3 million (up 648.47% YoY) and the FY2025 annual result came in at $287.2 million, up 4893.08% from the prior year.
• Income towards Parent Company declined to $34.4 million in Q1 2026, from $210.8 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $210.8 million in Q4 2025 to a low of -$37.6 million in Q1 2022.
• A 5-year average of $8.3 million and a median of -$9.0 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company slumped 49.62% — and 2025, when it jumped 14171.77%.
• Tracing AUPH's Income towards Parent Company over 5 years: stood at -$26.0 million in 2022, then retreated by 3.26% to -$26.9 million in 2023, then jumped by 105.5% to $1.5 million in 2024, then jumped by 14171.77% to $210.8 million in 2025, then tumbled by 83.7% to $34.4 million in 2026.
• The last three Income towards Parent Company figures came in at $34.4 million (Q1 2026), $210.8 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.